OOIR: Observatory of International Research

Papers

(The H4-Index of Kidney International Reports is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
COVID-19 Vaccination and Glomerulonephritis	139
Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2	131
De Novo ANCA-Associated Vasculitis With Glomerulonephritis in COVID-19	112
Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy	98
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD	95
A Systematic Review of Immune Checkpoint Inhibitor–Associated Glomerular Disease	95
Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations	90
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy	80
Safety of Remdesivir in Patients With Acute Kidney Injury or CKD	76
Roxadustat for CKD-related Anemia in Non-dialysis Patients	73
Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events	67
A Systematic Review of COVID-19 and Kidney Transplantation	65
A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study	64
IgA Vasculitis With Nephritis (Henoch−Schönlein Purpura) in a COVID-19 Patient	63
Complement in Secondary Thrombotic Microangiopathy	63
Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance	61
Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease	58
Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era	52
Dialysis-Induced Cardiovascular and Multiorgan Morbidity	49
Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD	49
Decreasing Incidence of Acute Kidney Injury in Patients with COVID-19 Critical Illness in New York City	48
Surgical Management of Secondary Hyperparathyroidism	48
Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria	48
Uric Acid and Chronic Kidney Disease: Still More to Do	47
Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephritis Following the Pfizer-BioNTech COVID-19 Vaccine	46

Rituximab in Membranous Nephropathy	45
Frailty in CKD and Transplantation	43
Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria	43
Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives	41
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists	39
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD	38
Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients	38
Toxic Nephropathy Secondary to Chronic Mercury Poisoning: Clinical Characteristics and Outcomes	37
Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics	37
Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease	36
Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in Nephrology Practice Across Countries	36